SCHEMBL2098199

SCHEMBL2098199

CCCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 15/20 1.00
CDK5 Q00535 12/20 1.00
CDK2 P24941 10/20 0.85
CCNE1 P24864 8/20 0.85
CDK7 P50613 7/20 0.85
CCNB1 P14635 5/20 0.85
CDK9 P50750 4/20 0.85
CDK4 P11802 4/20 0.85
CCND1 P24385 4/20 0.85
MAPK1 P28482 4/20 0.85
CCNH P51946 4/20 0.85
CCNE2 O96020 3/20 0.85
CSNK1D P48730 2/20 0.85
CLK2 P49760 2/20 0.85
CSNK1G2 P78368 2/20 0.85
DYRK1A Q13627 2/20 0.85
CLK4 Q9HAZ1 2/20 0.85
CSNK1G1 Q9HCP0 2/20 0.85
CCNK O75909 2/20 0.85
CCNA2 P20248 2/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1213597 1.00 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
SCHEMBL7113550 0.94 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
SCHEMBL7155510 0.94 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
SCHEMBL4285144 0.94 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
(S)-Roscovitine SCHEMBL29415376 0.92 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
(Rs)-Roscovitine SCHEMBL172593 0.92 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
Seliciclib SCHEMBL94728 0.92 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
(S)-Roscovitine SCHEMBL2907488 0.92 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
(Rs)-Roscovitine SCHEMBL15163619 0.92 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7
SCHEMBL4276454 0.90 CDK1 (1.00) CDK1CDK5CDK2CCNE1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163762-B2 Purine derivatives having, in particular, anti-proliferative properties, and their biological uses CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2012-04-24 US claimed
US-20100273802-A1 NEW PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) 2010-10-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273802-A1 NEW PURINE DERIVATIVES HAVING, IN PARTICULAR, ANTI-PROLIFERATIVE PROPERTIES, AND THEIR BIOLOGICAL USES PNP, TYMP, DPYD CDK1 404/4885CDK5 324/4885CDK2 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.